The University of Chicago Header Logo

Vedolizumab for perianal fistulizing Crohn's disease: systematic review and meta-analysis.

Vedolizumab for perianal fistulizing Crohn's disease: systematic review and meta-analysis. Intest Res. 2022 Apr; 20(2):240-250.

View in: PubMed